药明生物(02269.HK)合作伙伴旗下Sotrovimab获美国FDA紧急使用授权治疗新冠肺炎
药明生物((02269.HK)公布,公司祝贺合作伙伴Vir Biotechnology抗新冠治疗中和抗体sotrovimab获得美国FDA授予紧急使用授权(EUA)。这也是继去年2月药明生物与Vir公司宣布就抗新冠中和抗体达成全球研发合作後的又一大喜讯。
Sotrovimab(VIR-7831)是由Vir公司和葛兰素史克共同开发的一款单剂量在研单克隆抗体,用於治疗轻度至中度COVID-19成人和儿科患者。临床试验结果显示,Sotrovimab有助於降低高风险COVID-19患者住院或死亡风险,相关数据已披露在5月26日Vir发布的新闻稿。
药明生物首席执行官陈智胜博士表示“在如此短的时间内实现EUA几乎是不可能完成的任务,公司非常荣幸见证这一不可能变为现实,见证抗击新冠疫情历程中的里程碑。这也是药明生物赋能合作伙伴抗击新冠疫情最有力的证明之一。(wl/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.